241 related articles for article (PubMed ID: 27399166)
1. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
Tsujimoto S; Yanagimachi M; Tanoshima R; Urayama KY; Tanaka F; Aida N; Goto H; Ito S
Pediatr Blood Cancer; 2016 Nov; 63(11):1983-9. PubMed ID: 27399166
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
3. The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study.
Roszkiewicz J; Michałek D; Ryk A; Swacha Z; Szmyd B; Smolewska E
Int J Rheum Dis; 2020 Nov; 23(11):1505-1513. PubMed ID: 32969158
[TBL] [Abstract][Full Text] [Related]
4. The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate.
Soukup T; Dosedel M; Nekvindova J; Antonin Kubena A; Tacheci I; Duintjer Tebbens J; Vlcek J; Bradna P; Barvik I; Pavek P
Pharmacogenet Genomics; 2017 Feb; 27(2):43-50. PubMed ID: 27846189
[TBL] [Abstract][Full Text] [Related]
5. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
6. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
[TBL] [Abstract][Full Text] [Related]
7. Correlating pathology with the clinical symptoms of methotrexate-induced leukoencephalopathy in a child with relapsed T-cell acute lymphoblastic leukemia.
Summers RJ; Abramowsky CR; Cooper TM
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e19-22. PubMed ID: 23274378
[TBL] [Abstract][Full Text] [Related]
8. Analysis of association of ADORA
Grk M; Milic V; Dolzan V; Maksimovic N; Damnjanovic T; Pjevic MD; Pesic M; Novakovic I; Jekic B
Pharmacogenomics J; 2020 Dec; 20(6):784-791. PubMed ID: 32448869
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
10. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Zhao M; Liang L; Ji L; Chen D; Zhang Y; Zhu Y; Ongaro A
Pharmacogenomics; 2016 Jun; 17(9):1005-17. PubMed ID: 27270164
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of methotrexate-induced stroke-like neurotoxicity.
Watanabe K; Arakawa Y; Oguma E; Uehara T; Yanagi M; Oyama C; Ikeda Y; Sasaki K; Isobe K; Mori M; Hanada R; Koh K
Int J Hematol; 2018 Dec; 108(6):630-636. PubMed ID: 30182170
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group.
Duffner PK; Armstrong FD; Chen L; Helton KJ; Brecher ML; Bell B; Chauvenet AR
J Pediatr Hematol Oncol; 2014 Jan; 36(1):8-15. PubMed ID: 24345882
[TBL] [Abstract][Full Text] [Related]
14. ADORA2A Polymorphisms Influence Methotrexate Adverse Events in Rheumatoid Arthritis.
Kobold N; Jenko B; Tomšič M; Dolžan V; Praprotnik S
Isr Med Assoc J; 2019 May; 21(5):333-338. PubMed ID: 31140226
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
Vagace JM; Caceres-Marzal C; Jimenez M; Casado MS; de Murillo SG; Gervasini G
Am J Hematol; 2011 Jan; 86(1):98-101. PubMed ID: 21064136
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
D'Angelo V; Ramaglia M; Iannotta A; Addeo R
Expert Rev Hematol; 2014 Oct; 7(5):517-9. PubMed ID: 25213457
[No Abstract] [Full Text] [Related]
17. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.
Ruiz-Argüelles GJ; Coconi-Linares LN; Garcés-Eisele J; Reyes-Núñez V
Hematology; 2007 Oct; 12(5):387-91. PubMed ID: 17891601
[TBL] [Abstract][Full Text] [Related]
18. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
20. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
